Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zanubrutinib, Rituximab, and R-DHAOx in Newly Diagnosed MCL
NCT04624958Phase 2Active, not recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2020
- Primary completion
- Dec 2024
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of zanubrutinib in mantle cell lymphoma (MCL), sponsored by Sun Yat-sen University. Started Dec 2020; status: active, not recruiting.
02
Drugs
zanubrutinib
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT04624958.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04624958.